Cystathionine Levels in Patients With Huntington Disease

N A Aziz1, W Onkenhout2, H J Kerstens2

  • 1Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands.

Plos Currents
|October 6, 2015
PubMed

Insights

Plasma and urine cystathionine levels did not differ between early-stage Huntington disease (HD) patients and controls. These findings suggest cystathionine is not a useful biomarker for HD progression.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Genetics

Background:

  • Huntington disease (HD) is associated with reduced cystathionine γ-lyase (CSE) activity.
  • CSE is crucial for cysteine synthesis from cystathionine.

Purpose of the Study:

  • To investigate if blood and urine cystathionine levels are elevated in HD patients.
  • To determine if cystathionine levels correlate with HD progression.

Main Methods:

  • Measured cystathionine and 22 other amino acids in plasma and urine.
  • Included nine early-stage HD patients and nine matched controls.

Main Results:

  • No significant differences in plasma or urine cystathionine concentrations were observed between HD patients and controls.
  • No significant differences were found for any other measured amino acids.

Conclusions:

  • Plasma and urine cystathionine levels do not change in early-stage HD.
  • Cystathionine is unlikely to serve as a reliable biomarker for Huntington disease.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
767
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
258